Side effects and precautions for subcutaneous injection of evantuzumab (Rybrevant Faspro)

Subcutaneous evantumumab (Rybrevant Faspro) is an innovative treatment for adults with non-small cell lung cancer (NSCLC) , especially those who have spread to other parts of the body or require treatment because they cannot be surgically removed. This drug mainly targets tumors with specific abnormal epidermal growth factor receptor (EGFR) genes, and improves the therapeutic effect by combining it with other drugs, such as lazertinib, carboplatin and pemetrexed. However, patients need to be aware of possible side effects and corresponding precautions when using evantumumab.

During treatment with evantumumab, patients may experience a variety of common adverse reactions. According to clinical study data, more than 20% of patients reported the following side effects when used in combination with lazertinib: rash, nail lesions, musculoskeletal pain, fatigue, stomatitis, edema, nausea, diarrhea, vomiting, constipation, loss of appetite, and headache. In addition, patients may develop some laboratory abnormalities during treatment, such as decreased lymphocyte count, decreased sodium and potassium levels, decreased albumin, increased alanine aminotransferase and aspartate aminotransferase, decreased platelet count, increased gamma-glutamyl transferase, and decreased hemoglobin, which require regular monitoring.

When using evantumumab, patients also need to pay special attention to some serious warnings and precautions, including allergic and administration-related reactions, interstitial lung disease(ILD)/pneumonitis, venous thromboembolism (VTE) events when combined with lazertinib, serious adverse skin reactions, ocular toxicity, and embryo-fetal toxicity.

In conclusion, although evantumumab brings new hope for the treatment of non-small cell lung cancer, understanding its side effects and precautions is crucial to the patient's treatment process. Following your doctor's advice and conducting regular check-ups can not only effectively manage side effects, but also improve the success rate of treatment and quality of life.

References:https://www.drugs.com/newdrugs/fda-approves-rybrevant-faspro-amivantamab-hyaluronidase-lpuj-egfr-mutated-non-small-cell-lung-cancer-6697.html